Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 81.16

-0.9%

Dec 5 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zeta1961 who wrote (1656)	4/4/2006 12:15:28 AM
From: Jibacoa	of 3722

ALthough the P2 results of NYMX's NX-1207 on BPH were known in January, it wasn't until Dutton Research on March 10 recommended it as a"strong speculative buy" with a "target" around $6.25 that the stock had the spike.<g> Dutton said:"We believe a major reason to invest in Nymox Pharmaceutical Corporation is related to the potential of the Company's NX-1207 for benign prostatic hyperplasia (BPH)." They had already recommended the stock in November & last week it presented at Dutton's "Recognizing Opportunity" SmallCap Conference. They said that NX-1207 is on track to enter PIII in 2006. So far, on its PII it has shown highly significant efficacy without significant adverse side effects or safety problems. The stock seems to be founding support at the $4 level.The insiders hold more than 50% but the Debt/Eqt ratio is large & it sales around 285xBV <g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next